lobbying_activities: 746039
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 746039 | 11a4a809-32f3-468d-8846-d17a546e012b | Q1 | MEHLMAN CONSULTING, INC. | 284950 | ASTRAZENECA PHARMACEUTICALS | 2009 | first_quarter | MMM | Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act. Discussions and possible legislation amending Title SVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2009-04-08T18:03:57-04:00 |